SUBSCRIBE
SUBSCRIBE
News   Policy

Biogen Idec, Inc. (Massachusetts), Roche Holding AG’s Genentech End Dispute Over Rituxan Follow-Ons

October 22, 2010 | 
1 min read
Oct 21 (Reuters) - Biogen Idec Inc (BIIB.O) and Roche Holding AG's (ROG.VX) Genentech unit agreed to amend the terms of their collaboration to develop antibody drugs, ending a long-term dispute.
Legal
Genentech, Inc. Biogen
MORE ON THIS TOPIC
Pictured: Front view of the CDC museum in Georgia
CDC
RFK Jr. Appoints 2 New Advisors to CDC Vaccine Panel Ahead of March Meeting
March 2, 2026
 · 
2 min read
 · 
Tristan Manalac
Borrow money from friend, debt and loan, incentive or bonus payment, credit or lending concept, businessman hand giving money banknote to friend's hand.
FDA
FDA To Offer Bonus Payments for Speedy Drug Reviewers
February 27, 2026
 · 
1 min read
 · 
Annalee Armstrong
Digital compass. Business strategic explorer, Vision crisis, Mission path, Agency creative, Digital strategy, Market decision, Achievement strategy, Financial stock, Company vision concepts
Policy
FDA Policy Tracker 2026: One-Trial Drug Applications, Guidelines for Personalized Therapies
February 27, 2026
 · 
7 min read
 · 
BioSpace Editorial Staff
President Donald Trump calls out the first patient to access his TrumpRx drug platform during his State of the Union address at the U.S. Capitol on Tuesday, February 24, 2026.
Drug pricing
Trump Calls on Congress To Codify Most Favored Nation Drug Pricing in SOTU
February 25, 2026
 · 
2 min read
 · 
Annalee Armstrong